Expression of receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists

Clinical Cancer Research

Volumn 16, Issue 18, 2010, Pages 4675-7680

  Liu, Stephen V ^a   Schally, Andrew V ^b   Hawes, Debra ^a   Xiong, Shigang ^a   Fazli, Laden ^c   Gleave, Martin ^c   Cai, Jie ^a   Groshen, Susan ^a   Brands, Frank ^a   Engel, Juergen ^d   Pinski, Jacek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Aeterna Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GONADORELIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEPTOR DOWN REGULATION;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; TREATMENT FAILURE;

EID: 77956667524     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1113     Document Type: Article

References (23)

1. American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society; 2008.
2. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596-605.
3. Pinski J, Lamharzi N, Halmos G, et al. Chronic administration of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LH-RH receptor messenger ribonucleic acid levels in rats. Endocrinology 1996;137:3430-6. (Pubitemid 26250195)
4. Lamharzi N, Halmos G, Armatis P, Schally AV. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 1998;12:671-5. (Pubitemid 28097300)
5. Jungwirth A, Pinski J, Galvan G, et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997;33:1141-8. (Pubitemid 27310789)
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
7. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
8. Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005;73:851-9. (Pubitemid 41507486)
9. Straub B, Muller M, Krause H, et al. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone refractory human prostate cancers. Clin Cancer Res 2001;7:2340-3. (Pubitemid 32751633)
10. Volker P, Grundker C, Schmidt O, Schulz KD, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogs. Am J Obstet Gynecol 2002;186:171-9. (Pubitemid 34165428)
11. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994;55:144-8. (Pubitemid 24336135)
12. Friess H, Buchler M, Kiesel L, Kruger M, Beger HG. LH-RH receptors in the human pancreas. Basis for anti-hormonal treatment in ductal carcinoma of the pancreas. Int J Pancreatol 1991;10:151-9.
13. Ben-Yehudah A, Lorberboum-Galski H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther 2004;4:151-61. (Pubitemid 38208494)
14. Sion-Vardi N, Kaneti J, Segal-Abramson T, Giat J, Levy J, Sharoni Y. Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol 1992;148:1568-70.
15. Bahk JY, Kim MO, Park MS, et al. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urol Int 2008;80:431-8.
16. Baumann KH, Kiesel L, Kaufmann M, Bastert G, Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993;25:37-46. (Pubitemid 23107734)
17. Straub B, Muller M, Krause H, Schrader M, Miller K. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 2003;62:172-6. (Pubitemid 36802109)
18. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-9. (Pubitemid 30060537)
19. Szabo J, Vegh A, Racz G, Szende B. Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma. Urol Oncol 2005;23:399-401. (Pubitemid 41654505)
20. Straub B, Muller M, Krause H, Schrader M, Goessl C, Miller K. Receptor gene messenger RNA expression in metastatic lesions of prostate cancer. J Urology 2002;168:1212-4.
21. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300-10. (Pubitemid 39193184)
22. Pinski J, Schally AV, Yano T, et al. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate 1993;23:165-78. (Pubitemid 23289897)
23. Emons G, Sindermann H, Engel J, Schally AV, Grundker C. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 2009;90:15-8.